Rocklatan Retinal Perfusion OCT Study
Key facts
- Where
- Portland, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Casey Eye Institute, Oregon Health & Science UniversityPortland, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oregon Health and Science University
- Trial code
- NCT07174401
- Record updated
- 24 December 2025
- Original description
The main purpose of this study is to learn more about how Rocklatan eye drops affects blood flow in the eye. The secondary purpose is to see if our study devices can detect changes in blood flow before and after instillation of Rocklatan.Read full original descriptionShow less
Rocklatan Trial With Optical Coherence Tomography Study of Retinal Perfusion
The main purpose of this study is to learn more about how Rocklatan eye drops affects blood flow in the eye. The secondary purpose is to see if our study devices can detect changes in blood flow before and after instillation of Rocklatan.
Inclusion: Patients with both eyes with open angle glaucoma; Abnormal VF (glaucomatous pattern with PSD abnormal at p<0.05 or GHT outside normal limits) on most recent two clinic visits on chart review; Glaucomatous disc abnormality on chart review and confirmed on baseline disc photograph; Overall average NFL thickness > 55 μm measured by Heidelberg Spectralis OCT -Glaucoma Module Premium Edition (chart review), consistent with early glaucoma; NFLP-CD deficit (below 5 percentile of normal) in any of the 8 sectors on the initial baseline visit; The difference in baseline NFLP-CD between the left and right eye should be less than 5% (% of area); IOP >= 17 mm Hg on the most recent two clinic visits (chart review) after monotherapy with latanoprost in both eyes.
Exclusion: Eye disease that could affect VF, NFL thickness, or NFLP (e.g., visually significant cataract, AMD, diabetic retinopathy, and optic neuropathy) at any study visit; Age < 21 years at baseline; Best corrected visual acuity worse than 20/30 on chart review of most recent clinic visit; OCT and OCTA scans not meeting quality criteria at baseline; Inability to cooperate with study procedures; Inability to commit to the study visits.